News
Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...
Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...
Zacks Investment Research on MSN3d
Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase IIIAmgen AMGN announced encouraging new data from its interim analysis of the global late-stage study evaluating Imdelltra ...
Small cell lung cancer (SCLC) accounts for 10-15% of all lung cancer cases annually, with 250,000 incident cases diagnosed ...
Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease ...
Stocktwits on MSN4d
Amgen Says Its Drug Reduces Risk Of Death By 40% In Small Cell Lung Cancer: Retail’s Yet To Be ConvincedShares of Amgen (AMGN) were in the spotlight on Monday morning after the company announced that its immunotherapy Imdelltra ...
Amgen said interim results from a Phase 3 trial showed Imdelltra reduced the risk of death and other benefits for patients with small cell lung cancer.
MedPage Today on MSN3d
'Immediately Practice-Changing' Trial in Small Cell Lung CancerCHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...
THOUSAND OAKS, Calif., June 2, 2025 /PRNewswire/ -- Amgen (AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA ® (tarlatamab-dlle) reduced the ...
Amgen (NasdaqGS:AMGN) recently announced interim results from its Phase 3 DeLLphi-304 trial for IMDELLTRA, showing ...
Amgen AMGN announced encouraging new data from its interim analysis of the global late-stage study evaluating Imdelltra (tarlatamab-dlle) for treating patients with small cell lung cancer (SCLC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback